The University of Chicago Header Logo

Connection

Michael Charlton to Non-alcoholic Fatty Liver Disease

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Non-alcoholic Fatty Liver Disease.
Michael Charlton
Connection Strength
10.683
Non-alcoholic Fatty Liver Disease
  1. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol. 2023 May 19; 23(1):160.
    View in: PubMed
    Score: 0.709
  2. Rational combination therapy for NASH: Insights from clinical trials and error. J Hepatol. 2023 05; 78(5):1073-1079.
    View in: PubMed
    Score: 0.691
  3. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020 Jul; 55(7):722-730.
    View in: PubMed
    Score: 0.573
  4. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl. 2020 01; 26(1):141-159.
    View in: PubMed
    Score: 0.557
  5. The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. Hepatology. 2019 03; 69(3):931-933.
    View in: PubMed
    Score: 0.528
  6. Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts. Transplantation. 2019 01; 103(1):1-2.
    View in: PubMed
    Score: 0.523
  7. FGF-19 agonism for NASH: a short study of a long disease. Lancet. 2018 03 24; 391(10126):1124-1126.
    View in: PubMed
    Score: 0.494
  8. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clin Liver Dis. 2018 02; 22(1):201-211.
    View in: PubMed
    Score: 0.491
  9. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 01; 312(6):G666-G680.
    View in: PubMed
    Score: 0.460
  10. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.456
  11. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 May; 20(2):403-17.
    View in: PubMed
    Score: 0.435
  12. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
    View in: PubMed
    Score: 0.433
  13. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology. 2016 06; 150(8):1849-62.
    View in: PubMed
    Score: 0.431
  14. Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).
    View in: PubMed
    Score: 0.186
  15. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.186
  16. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.177
  17. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
    View in: PubMed
    Score: 0.176
  18. Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation. 2022 10 01; 106(10):2006-2018.
    View in: PubMed
    Score: 0.167
  19. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 2022 03 30; 12(3):e056159.
    View in: PubMed
    Score: 0.164
  20. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.162
  21. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 10; 10(10):1198-1208.
    View in: PubMed
    Score: 0.156
  22. Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. Semin Liver Dis. 2021 08; 41(3):225-234.
    View in: PubMed
    Score: 0.155
  23. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 09 01; 319(3):G333-G344.
    View in: PubMed
    Score: 0.146
  24. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.139
  25. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
    View in: PubMed
    Score: 0.129
  26. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 11; 155(5):1463-1473.e6.
    View in: PubMed
    Score: 0.127
  27. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.126
  28. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.126
  29. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.123
  30. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
    View in: PubMed
    Score: 0.123
  31. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
    View in: PubMed
    Score: 0.122
  32. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.120
  33. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016 Apr; 150(4):956-67.
    View in: PubMed
    Score: 0.106
  34. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul; 11(7):e1001680.
    View in: PubMed
    Score: 0.096
  35. Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease? Hepatology. 2014 May; 59(5):1668-70.
    View in: PubMed
    Score: 0.094
  36. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66.
    View in: PubMed
    Score: 0.092
  37. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013 Jun; 18(3):251-8.
    View in: PubMed
    Score: 0.089
  38. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21(9):1935-41.
    View in: PubMed
    Score: 0.089
  39. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32(2):279-86.
    View in: PubMed
    Score: 0.079
  40. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011 Nov; 301(5):G825-34.
    View in: PubMed
    Score: 0.078
  41. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53.
    View in: PubMed
    Score: 0.078
  42. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21(3):310-5.
    View in: PubMed
    Score: 0.076
  43. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology. 2011 Jan; 140(1):25-8.
    View in: PubMed
    Score: 0.075
  44. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun; 55(6):2005-23.
    View in: PubMed
    Score: 0.021
  45. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun; 107(6):811-26.
    View in: PubMed
    Score: 0.021
  46. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 Jun; 142(7):1592-609.
    View in: PubMed
    Score: 0.021
  47. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012 Apr; 57(4):952-7.
    View in: PubMed
    Score: 0.020
  48. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg. 2011 Nov; 21(11):1714-20.
    View in: PubMed
    Score: 0.020
  49. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011 Aug; 52(8):1517-25.
    View in: PubMed
    Score: 0.019
  50. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010 Dec; 20(12):1698-709.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.